Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
01:00am, Thursday, 28'th Apr 2022
April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
02:22pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.
This is what you should do in the stock market now, according to three 2022 fund-award winners
01:18pm, Saturday, 09'th Apr 2022 MarketWatch
Don't get out of equities and start to favor growth strategies.
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
12:24pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive rev
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
11:48am, Tuesday, 05'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
05:00am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
01:00am, Friday, 01'st Apr 2022
BREDA, the Netherlands--(BUSINESS WIRE)--argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
argenx announces full exercise of underwriters’ option to purchase additional ADSs
09:00pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Regulated information — Inside information
argenx announces Annual General Meeting of Shareholders on May 10, 2022
08:30pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
March 29, 2022
argenx announces closing of global offering
08:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Regulated information
argenx raises $700 million in gross proceeds in a global offering
01:00am, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
Regulated information — Inside information
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
12:42pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
09:47am, Wednesday, 23'rd Mar 2022
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
argenx announces launch of proposed global offering
08:15pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
Regulated information — Inside information
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
07:44pm, Tuesday, 22'nd Mar 2022 Benzinga
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-CO
